Currently only orlistat (Xenical), a drug which is considered to be acting through inhibition of pancreatic lipase enzyme, a key enzyme for the digestion of dietary triglycerides, has been approved by FDA and is available for long-term treatment of obesity. This evidence concerns the gene PNLIP and obesity due to melanocortin 4 receptor deficiency.